US2015010580A1PendingUtilityA1

Antibodies to clostridium difficile toxins

49
Assignee: SHONE CLIFFORD CHARLESPriority: Feb 20, 2009Filed: Mar 18, 2014Published: Jan 8, 2015
Est. expiryFeb 20, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Clifford ShoneJohn Landon
A61P 31/04C07K 16/1282A61K 2039/505C07K 2317/20
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.

Claims

exact text as granted — not AI-modified
1 . An antibody composition for prevention or treatment of  Clostridium difficile  infection, comprising ovine antibodies, wherein the antibodies bind to a  C. difficile  toxin. 
     
     
         2 . The antibody composition according to  claim 1 , wherein the antibodies are polyclonal antibodies. 
     
     
         3 . The antibody composition according to  claim 1 , wherein the antibodies bind to at least one  C. difficile  toxin selected from the group consisting of:  C. difficile  Toxin A,  C. difficile  Toxin B, and  C. difficile  Binary Toxin. 
     
     
         4 . The antibody composition according to  claim 3 , wherein the antibodies bind to  C. difficile  Toxin A and to  C. difficile  Toxin B. 
     
     
         5 . The antibody composition according to  claim 3 , wherein the antibodies bind to  C. difficile  Toxin A and to  C. difficile  Binary Toxin. 
     
     
         6 . The antibody composition according to  claim 3 , wherein the antibodies bind to  C. difficile  Toxin B and to  C. difficile  Binary Toxin. 
     
     
         7 . The antibody composition according to  claim 1 , wherein the  C. difficile  toxin is a Toxin A selected from the group consisting of: Toxinotype 0, Toxinotype III and Toxinotype V. 
     
     
         8 . The antibody composition according to  claim 1 , wherein the  C. difficile  toxin is a Toxin B selected from the group consisting of: Toxinotype 0, Toxinotype III and Toxinotype V. 
     
     
         9 . A pharmaceutical composition comprising the antibody composition according to  claim 1 , and at least one component selected from the group consisting of a pharmaceutically acceptable carrier, excipient, and salt for parenteral administration. 
     
     
         10 - 11 . (canceled) 
     
     
         12 . A method of producing ovine antibodies comprising
 (i) administering an immunogen comprising a  Clostridium difficile  toxin or a fragment thereof to a sheep,   (ii) allowing sufficient time for the generation of antibodies in the sheep, and   (iii) obtaining the antibodies from the sheep.   
     
     
         13 . The method according to  claim 12 , wherein the immunogen comprises a  C. difficile  toxoid. 
     
     
         14 . The pharmaceutical composition of  claim 9 , wherein the antibodies are polyclonal antibodies. 
     
     
         15 . The pharmaceutical composition of  claim 9 , wherein the antibodies bind to at least one  C. difficile  toxin selected from the group consisting of:  C. difficile  Toxin A,  C. difficile  Toxin B, and  C. difficile  Binary Toxin. 
     
     
         16 . The pharmaceutical composition of  claim 9 , wherein the antibodies bind to  C. difficile  Toxin A and to  C. difficile  Toxin B. 
     
     
         17 . The pharmaceutical composition of  claim 9 , wherein the antibodies bind to  C. difficile  Toxin A and to  C. difficile  Binary Toxin. 
     
     
         18 . The pharmaceutical composition of  claim 9 , wherein the antibodies bind to  C. difficile  Toxin B and to  C. difficile  Binary Toxin. 
     
     
         19 . The pharmaceutical composition of  claim 9 , wherein the  C. difficile  Toxin A is selected from the group consisting of: Toxinotype 0, Toxinotype III and Toxinotype V. 
     
     
         20 . The pharmaceutical composition of  claim 9 , wherein the  C. difficile  Toxin B is selected from the group consisting of: Toxinotype 0, Toxinotype III and Toxinotype V. 
     
     
         21 . A pharmaceutical composition comprising:
 ovine antibodies that bind to  Clostridium difficile  Toxin A,   ovine antibodies that bind to  C. difficile  Toxin B, and   at least one component selected from the group consisting of a pharmaceutically acceptable carrier, excipient, and salt for parental administration.   
     
     
         22 . The pharmaceutical composition of  claim 21 , further comprising ovine antibodies that bind to  C. difficile  Binary Toxin.

Join the waitlist — get patent alerts

Track US2015010580A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.